Year All20242023202220212020201920182017201620152014 ABIVAX ANNOUNCES THE RELEASE OF ITS 2020 HALF-YEAR FINANCIAL REPORT September 30, 2020 Read More ABIVAX presents first-half 2020 financial results and operations update September 24, 2020 Read More Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study September 02, 2020 Read More Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial July 02, 2020 Read More Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting June 22, 2020 Read More Abivax Receives € 5m Non-dilutive Financing from Société Générale as State Guaranteed Loan June 15, 2020 Read More Abivax publishes universal registration document 2020 "Document d'Enregistrement Universel" May 25, 2020 Read More Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial May 25, 2020 Read More Abivax postpones its Annual General Meeting to June 19, 2020 May 20, 2020 Read More €36 million non-dilutive funding from Bpifrance for ABIVAX’ ABX464 Covid-19 program May 15, 2020 Read More
Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study September 02, 2020 Read More
Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting June 22, 2020 Read More
Abivax Receives € 5m Non-dilutive Financing from Société Générale as State Guaranteed Loan June 15, 2020 Read More
Abivax publishes universal registration document 2020 "Document d'Enregistrement Universel" May 25, 2020 Read More
Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial May 25, 2020 Read More
€36 million non-dilutive funding from Bpifrance for ABIVAX’ ABX464 Covid-19 program May 15, 2020 Read More
